Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies c

Investors need to pay close attention to LQDA stock based on the movements in the options market lat

On August 28, 2026, Liquidia Corp (LQDA) shares experienced a decline of 3.1%, bringing the current

Liquidia Corporation is rated Sell due to YUTREPIA's decelerating growth and an overextended $6B+ va

Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make

LQDA's Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to

On August 20, 2026, Liquidia Corp (LQDA) shares fell 5.8% to $71.05, continuing a downward trend fro

Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-

Handelsbanken Fonder AB bought a new stake in Liquidia Corporation (NASDAQ: LQDA) during the second

Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product de

The shares had risen by 155% year-to-date prior to earnings. Regardless, its one commercialized drug

Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the compan

Liquidia targets more than $1 billion in 2027 net revenues as YUTREPIA gains share and funds a broad

Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Overweight and raise

Top analysts changed outlook on top names. Truist, Morgan Stanley, B of A Securities, HC Wainwright,

B of A Securities analyst Jason Gerberry maintains Liquidia (NASDAQ:LQDA) with a Neutral and rais

YUTREPIA's commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% seq

LifeSci Capital analyst Gaurav Maini downgrades Liquidia (NASDAQ:LQDA) from Outperform to Market

Needham analyst Serge Belanger maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price t

BTIG analyst Julian Harrison maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price tar

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript

Liquidia NASDAQ: LQDA reported second-quarter 2026 results marked by continued growth for its inhale

Liquidia Corporation (LQDA) came out with quarterly earnings of $0.74 per share, beating the Zacks C

Liquidia (NASDAQ:LQDA) reported quarterly earnings of $0.74 per share which beat the analyst consens

YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the

Liquidia, PBF Energy and Forum Energy Technologies pair low beta with positive momentum and growth d

Lenovo Group, Victoria's Secret and Liquidia Corporation are three stocks from very different indust

LQDA heads into its Q2 earnings with Yutrepia driving growth, rising profitability and a self-funded

MORRISVILLE, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharm

HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and ra

Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,

Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrad

B of A Securities analyst Jason Gerberry downgrades Liquidia (NASDAQ:LQDA) from Buy to Neutral an

Liquidia (NASDAQ:LQDA) released first-quarter financial results and hosted an earnings call on Monda

BTIG analyst Julian Harrison maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price tar

Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to

HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and ra

Liquidia Corp (LQDA) reported better-than-expected Q1 results, with earnings of 52 cents per share a

Wall Street analysts changed outlook on top names. For full view of analyst rating changes, see anal

HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and ra

Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Overweight and raise

Needham analyst Serge Belanger maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price t

BTIG analyst Julian Harrison maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price tar

US stocks rise, Nasdaq up 0.3%. Liquidia Corp (LQDA) beats Q1 expectations, shares rise 15.7%. Other

Liquidia (NASDAQ:LQDA) reported quarterly earnings of $0.52 per share which beat the analyst consens

Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Overweight and raise

Oppenheimer analyst Andreas Argyrides maintains Liquidia (NASDAQ:LQDA) with a Underperform and ra